SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network (BNAI) is experiencing a powerful surge driven by a recent $2 million deal with Valio Technologies, fueling significant speculation. This news, combined with a low float and substantial short interest, has ignited an intense short squeeze, prompting community discussions around anticipated parabolic runs. Investors are celebrating massive gains, with many holding over the weekend and comparing its potential to past high-flying stocks, while short sellers face considerable pressure.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

Q/C Technologies Inc. is generating significant buzz due to the recent appointment of OpenAI's Chelsea Voss to its board and the strategic involvement of Martin Shkreli. The community is actively discussing the company's potential as a quantum computing play, with many anticipating substantial price appreciation and a possible short squeeze given its low float. Investors are comparing its current setup to previous high-growth opportunities, fueling excitement for its future trajectory.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is trending due to advancements in its anticoagulation pipeline, including the Phase 3-ready tecarfarin with FDA Fast Track status and the recent acquisition of VLX-1005 for heparin-induced thrombocytopenia. Community sentiment is sharply divided, with supporters emphasizing the large market opportunity and collaborations like that with Abbott, while detractors express concerns over frequent offerings, cash burn, and perceived promotional activity.

SSgA Active Trust - State Street Utilities Select Sector SPDR ETF

Utilities Select Sector SPDR Fund

The Utilities Select Sector SPDR Fund ($XLU) is trending due to the increasing power demands from the AI boom, which is transforming the sector from a traditional defensive play into a growth opportunity. Community discussions highlight its dual appeal as a safe haven amidst broader market uncertainties and a beneficiary of a structural shift in electricity consumption. Many investors are actively monitoring its strong price action, considering it a crucial 'AI power play' within their portfolios.

Irys is a Layer 1 datachain that unifies onchain data storage and smart contract execution into a single network. Traditional smart contract chains handle financial transactions but lack native primitives for working with data at scale. Traditional datachains handle storage but lack integration with smart contracts. Irys serves both. Irys bridges this gap by unifying storage and execution, making data programmable through IrysVM, its native EVM execution layer. The network offers flexible storage options: users can choose between term storage (temporary, duration-based) or permanent storage (one-time payment for perpetual retention). Both operate at at-cost pricing, made possible by Irys's multi-revenue model that combines storage fees, execution fees, and programmable data transactions. This design allows Irys to remain competitive on price while maintaining economic sustainability. Irys achieves instant data retrieval and infinite horizontal scaling. As demand grows, the network expands capacity by adding validators who prove continuous maintenance of their assigned data partitions. The network's native token, $IRYS, is used for all storage and execution fees, as well as validator staking.

Irys

IRYS is actively trending following its recent availability on a major exchange, sparking a surge in trading volume and public awareness. Community sentiment is mixed, with many bullish traders highlighting its "low supply, high demand" and deflationary tokenomics, while others express caution regarding price volatility and suspected bot activity. Investors are discussing its potential in the broader context of programmable data chains and AI-related crypto trends.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy is generating significant buzz following the launch of its InDensity battery storage platform, touted for its high density and safety features critical for grid-scale and AI data center power demands. The community is keenly anticipating further updates and potential large-scale partnerships, alongside high short interest, as discussions around U.S. domestic battery solutions intensify.

Oasis is a layer-one blockchain built to support confidential applications at scale. It’s home to Sapphire, the world’s first private EVM network, Oasis Privacy Layer, a cross-chain privacy solution for any EVM dApp, and Runtime Offchain Logic, a framework that brings trustworthy off-chain computing, onchain. Powered by its ROSE token, Oasis leverages a unique layered architecture and native rollup support, making it ideal for use cases in AI, DeFi, DAOs, gaming, and more.

Oasis Network

Oasis Network (ROSE) is trending as the community intensely discusses its strategic rebrand and pivot towards "Rose AI," emphasizing its role in privacy-preserving AI and Web3 infrastructure. This focus, underpinned by ongoing grants, partnerships, and advancements with its Sapphire runtime for confidential AI and DeFi, drives conversations about ROSE's strengthened utility. Despite price fluctuations, many view ROSE as a pivotal project in the evolving privacy and AI narratives.

B2Gold Corp. is an exploration company, which engages in the acquisition and development of mineral properties. It operates through the following segments: Fekola Mine, Fekola Regional, Masbate Mine, Otjikoto Mine, Goose Project, Other Mineral Properties, and Corporate and Other. The Fekola Regional segment consists of Bantako North, Menankoto, Dandoko, and Bakolobi properties. The Other Mineral Properties segment focuses on the company interests in mineral properties which are at various stages of exploration and evaluation. The Corporate and Other segment includes the corporate operations. The company was founded by Mark Anthony Corra, Thomas A. Garagan, Clive Thomas Johnson, and Roger Thomas Richer on November 30, 2006 and is headquartered in Vancouver, Canada.

B2gold Corp

B2Gold is trending as the gold sector experiences a significant rally, driven by the approval of its Fekola Regional exploitation permit in Mali and the Goose Mine in Canada commencing commercial production. The community widely discusses the company's substantial undervaluation relative to surging gold prices and its expanding production profile, anticipating a notable re-rating and improved cash flow. Many investors see BTG as a compelling long-term opportunity, despite its perceived lag behind some peers.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is a major talking point amid swirling rumors of an improved takeover bid from Sanofi, following reports an earlier $16 per share offer was rejected. This, combined with the company's strategic acceleration of its AXPAXLI FDA submission pathway and a high-profile commercial officer hire, has the community actively debating the potential for strong clinical data or an imminent acquisition at a significant premium.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending amid anticipation for an upcoming regulatory decision on its Hunter Syndrome gene therapy, RGX-121, further boosted by a significant partnership with Nippon Shinyaku. The community is also intently discussing recent positive data for its Duchenne Muscular Dystrophy program, RGX-202, often comparing its safety profile favorably to competitors in the sector. Despite recent stock volatility and some short interest, investors are highlighting a deeply undervalued pipeline with multiple potential catalysts in gene therapy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
